{"id":"torsemide-and-spironolactone-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypokalemia"},{"rate":"5-10%","effect":"Hyponatremia"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Torsemide increases the excretion of sodium and chloride ions in the urine, leading to increased water excretion and a decrease in blood volume. Spironolactone, on the other hand, blocks the action of aldosterone, a hormone that promotes sodium retention and potassium excretion. This dual mechanism of action allows for effective diuresis and blood pressure reduction.","oneSentence":"Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, while spironolactone is a potassium-sparing diuretic that works by antagonizing the aldosterone receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:35.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema"}]},"trialDetails":[{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT06039592","phase":"","title":"Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":164},{"nctId":"NCT06039540","phase":"","title":"Study of Drug Therapy for Pediatric Heart Failure","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-01-01","conditions":"Heart Failure Congenital","enrollment":200},{"nctId":"NCT06037434","phase":"","title":"Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2022-04-01","conditions":"Congenital Mitral Insufficiency","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Torsemide and Spironolactone tablet","genericName":"Torsemide and Spironolactone tablet","companyName":"Sarfez Pharmaceuticals, Inc.","companyId":"sarfez-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, while spironolactone is a potassium-sparing diuretic that works by antagonizing the aldosterone receptor. Used for Hypertension, Edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}